Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 57, Issue 9, 2016, Pages 2171-2179

  Camus, Vincent ^a,b   Sarafan Vasseur, Nasrin ^b   Bohers, Elodie ^b   Dubois, Sydney ^b   Mareschal, Sylvain ^b   Bertrand, Philippe ^b   Viailly, Pierre Julien ^b   Ruminy, Philippe ^b   Maingonnat, Catherine ^b   Lemasle, Emilie ^a,b   Stamatoullas, Aspasia ^a,b   Picquenot, Jean Michel ^a   Cornic, Marie ^a   Beaussire, Ludivine ^b   Bastard, Christian ^a,b   Frebourg, Thierry ^b   Tilly, Hervé ^a,b   Jardin, Fabrice ^a,b  

^a CENTRE HENRI BECQUEREL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

Circulating DNA; digital PCR; DLBCL; exportin 1; somatic mutations

Indexed keywords

CIRCULATING FREE DNA; DNA; EXPORTIN 1; MYELOID DIFFERENTIATION FACTOR 88; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL RECEPTOR; EXPORTIN 1 PROTEIN; KARYOPHERIN; MYD88 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIGITAL POLYMERASE CHAIN REACTION; FEMALE; FOLLOW UP; GENE FREQUENCY; HUMAN; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPRODUCIBILITY; SOMATIC MUTATION; BLOOD; CANCER STAGING; DIAGNOSTIC IMAGING; DIFFUSE LARGE B CELL LYMPHOMA; GENETICS; HIGH THROUGHPUT SEQUENCING; LIQUID BIOPSY; MUTATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KARYOPHERINS; LIQUID BIOPSY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECURRENCE;

EID: 84958534910     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2016.1139703     Document Type: Article

References (43)

1. H.Tilly, U.Vitolo, J.Walewski, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii78–vii82.
2. J.Ferlay, I.Soerjomataram, R.Dikshit, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer J Int Cancer. 2015;136:E359–E386.
3. J.W.Friedberg Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:498–505.
4. L.A.Diaz, A.Bardelli Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–586.
5. E.Bohers, P.J.Viailly, S.Dubois, et al. Somatic mutations of cell-free circulating DNA detected by Next Generation Sequencing reflect the genetic changes in both Germinal Center B-cell like and activated B-cell like diffuse large B-cell lymphoma tumors at the time of diagnosis. Haematologica. 2015;100:e280–4. DOI: 10.3324/haematol.2015.123612.
6. P.Mancuso, A.Calleri, P.Antoniotti, et al. If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer. 2010;10:644.
7. K.Jung, C.Stephan, M.Lewandowski, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 2004;205:173–180.
8. G.Sozzi, D.Conte, M.Leon, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:3902–3908.
9. M.Frattini, G.Gallino, S.Signoroni, et al. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N Y Acad Sci. 2006;1075:185–190.
10. S.A.Leon, B.Shapiro, D.M.Sklaroff, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650.
11. C.Bettegowda, M.Sausen, R.J.Leary, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
12. H.-G.Goh, M.Lin, T.Fukushima, et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma. 2011;52:896–904.
13. C.M.Hindson, J.R.Chevillet, H.A.Briggs, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013;10:1003–1005.
14. F.Jardin, A.Pujals, L.Pelletier, et al. Whole exome sequencing of refractory aggressive B-cell lymphomas identified recurrent mutations of the exportin-1 gene (XPO1) in primary mediastinal B-cell lymphoma subtype. A LYSA study [abstract]. Hematol Oncol. 2015;33(suppl S1):100–180 [Abstract 048].
15. S.Mareschal, S.Dubois, P.-J.Viailly, et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma: exome sequencing of refractory DLBCL. Genes Chromosomes Cancer. 2016;55:251–267. DOI: 10.1002/gcc.22328.
16. S.Dubois, S.Mareschal, J.-M.Picquenot, et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget. 2015;6:16712–16724.
17. M.T.McCabe, H.M.Ott, G.Ganji, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492:108–112.
18. S.K.Knutson, S.Kawano, Y.Minoshima, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13:842–854.
19. E.Bohers, S.Mareschal, A.Bouzelfen, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2014;53:144–153.
20. V.N.Ngo, R.M.Young, R.Schmitz, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–119.
21. W.H.Wilson, R.M.Young, R.Schmitz, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–926. DOI: 10.1038/nm.3884.
22. C.P.Hans, D.D.Weisenburger, T.C.Greiner, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
23. M.Baker Digital PCR hits its stride. Nat Methods. 2012;9:541–544.
24. J.A.Beaver, D.Jelovac, S.Balukrishna, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014;20:2643–2650.
25. D.Sefrioui, A.Perdrix, N.Sarafan-Vasseur, et al. Short report: monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Int J Cancer. 2015;137:2513–2519 DOI: 10.1002/ijc.29612.
26. D.A.Armbruster, T.Pry Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29:S49–S52.
27. G.Schiavon, S.Hrebien, I.Garcia-Murillas, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7:313ra182.
28. V.Taly, D.Pekin, L.Benhaim, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem. 2013;59:1722–1731.
29. A.A.Tone, M.K.McConechy, W.Yang, et al. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer. 2014;14:982.
30. P.Laurent-Puig, D.Pekin, C.Normand, et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:1087–1097.
31. S.-J.Dawson, J.F.Seymour Large B-cell lymphoma: is the future written in the blood? Lancet Oncol. 2015;16:481–483.
32. M.Roschewski, K.Dunleavy, S.Pittaluga, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16:541–549.
33. S.Yamada, Y.Ishida, A.Matsuno, et al. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma. 2015;56:2141–2145. DOI: 10.3109/10428194.2014.979413.
34. I.Bonzheim, S.Giese, C.Deuter, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015;126:76–79.
35. A.A.Alizadeh, M.B.Eisen, R.E.Davis, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
36. M.Compagno, W.K.Lim, A.Grunn, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459:717–721.
37. R.E.Davis, V.N.Ngo, G.Lenz, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.
38. Z.A.Hing, R.Mantel, K.A.Beckwith, et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 2015;125:3128–3132.
39. V.Ribrag, J.Soria, L.Reyderman, et al. Phase I study of E7438 (EPZ-6438), an enhancer of zeste-homolog 2 (EZH2) inhibitor: dose determination and preliminary activity in non-Hodgkin lymphoma [abstract]. Hematol Oncol. 2015;33(suppl S1):100–180 [Abstract 145].
40. D.Chaudhary, L.Werner, R.Improgo, et al. Effect of MYD88 mutation in CLL on IRAK4 and BTK inhibition in vitro. Blood. 2013;122:4132–4132.
41. V.Caner, N.Sen Turk, I.C.Baris, et al. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas. Genet Test Mol Biomarkers. 2015;19:372–378.
42. D.M.Kurtz, M.R.Green, S.V.Bratman, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679–3687.
43. F.Leithäuser, M.Bäuerle, M.Q.Huynh, et al. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood. 2001;98:2762–2770.